Deal Watch: Auxilium Joins The Tax-Inversion Wave As BIO Keeps The Deal Tide High
Endo expanded its generics business by purchasing Dava, EMD Serono partnered with Mersana on antibody-drug conjugates and Ligand in-licensed a cancer and autoimmune disease candidate from TG Therapeutics. It was all part of a hectic deal-making week coinciding with the annual BIO conference in San Diego.
You may also be interested in...
Deal Watch: Lilly And AZ Team Up In Alzheimer’s In Latest Big Pharma Pairing
Boehringer Ingelheim signs a cancer immunotherapy deal with CureVac and Endo pursues Auxilium, while Merck KGaA inks multiple deals to add to its dwindling pipeline and Sanofi teams up with MyoKardia in heart disease.
Endo Makes A Play For Auxilium, But QLT Deal Gets In The Way
The Irish company made its interest for Auxilium public, but the takeover target is not ready to break its previous merger agreement with Canadian drugmaker QLT.
Deal Watch: Salix Merges With Italy’s Cosmo In Latest Tax-Inversion Play
A research agreement between AstraZeneca and Germany’s Max Planck Institute and a development pact between Portola and Daiichi Sankyo for an adverse-bleeding therapy highlight the week’s deal-making. In addition, HealthCare Royalty Partners announced a new royalty deal with Supernus and reworked its 2012 loan with Raptor, while GlobeImmune went public on its second IPO attempt.